{
    "clinical_study": {
        "@rank": "63698", 
        "acronym": "MAJESTIC", 
        "arm_group": {
            "arm_group_label": "Test device arm  (DES SFA)", 
            "arm_group_type": "Experimental", 
            "description": "Patients in this arm will receive the study device: the Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)"
        }, 
        "brief_summary": {
            "textblock": "To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable\n      performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal\n      Artery (PPA) lesions."
        }, 
        "brief_title": "Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Atherosclerosis of Native Arteries of the Extremities", 
        "condition_browse": {
            "mesh_term": "Atherosclerosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects age 18 and older\n\n          -  Subject (or Legal Guardian if applicable) has signed the consent form and is willing\n             and able to provide consent before any study-specific tests or procedures are\n             performed and agrees to attend all required follow-up visits\n\n          -  Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3 or 4\n\n          -  Stenotic, restenotic (from angioplasty only, previous treatment with drug coated\n             balloon is not allowed) or occlusive lesion(s) located in the native superficial\n             femoral artery or proximal popliteal artery:\n\n               1. Degree of stenosis \u226570% by visual angiographic assessment\n\n               2. Vessel diameter \u2265 4 and \u2264 6mm\n\n               3. Total lesion length (or series of lesions) \u226530 mm and \u2264110 mm\n\n                    -  (Note:  tandem lesions may be treated, provided that the tandem lesion\n                       segment can be covered with only one stent)\n\n               4. Target lesion located at least three centimeters above the inferior edge of the\n                  femur\n\n          -  Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with\n             at least one of three vessels patent (<50% stenosis) to the ankle or foot"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820637", 
            "org_study_id": "S2049"
        }, 
        "intervention": {
            "arm_group_label": "Test device arm  (DES SFA)", 
            "description": "Drug-eluting SFA self-expanding stent", 
            "intervention_name": "The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "atherosclerosis", 
            "SFA", 
            "PPA", 
            "lower extremities", 
            "stenting", 
            "paclitaxel"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Camperdown", 
                        "country": "Australia"
                    }, 
                    "name": "Royal Prince Alfred Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Randwick", 
                        "country": "Australia"
                    }, 
                    "name": "Prince of Wales Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna, Austria", 
                        "country": "Austria"
                    }, 
                    "name": "Allgemeines Krankenhaus AKH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dendermonde", 
                        "country": "Belgium", 
                        "zip": "9200"
                    }, 
                    "name": "AZ Sint-Blasius"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium"
                    }, 
                    "name": "Ziekenhuis Oost Limburg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tienen", 
                        "country": "Belgium", 
                        "zip": "3300"
                    }, 
                    "name": "Regionaal Ziekenhuis Heilig Hart Tienen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bad Krozingen", 
                        "country": "Germany"
                    }, 
                    "name": "Universit\u00e4ts-Herzzentrum Freiburg Bad Krozingen GmbH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Flensburg", 
                        "country": "Germany"
                    }, 
                    "name": "Ev. Luth. Diakonissenanstalt Flensburg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany"
                    }, 
                    "name": "Universit\u00e4tsklinikum Heidelberg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany"
                    }, 
                    "name": "Herzzentrum Universit\u00e4t Leipzig"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand"
                    }, 
                    "name": "Auckland City Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "New Zealand"
                    }, 
                    "name": "Braemar Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Otahuhu", 
                        "country": "New Zealand"
                    }, 
                    "name": "Middlemore Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Austria", 
                "Belgium", 
                "Germany", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project With Boston Scientific's Innova Drug Eluting Stent", 
        "other_outcome": {
            "description": "Major Adverse Events (MAEs) defined as all causes of death through 1 month, target limb major amputation through 9 months and/or target lesion revascularization through 9 months", 
            "measure": "MAE rate", 
            "safety_issue": "Yes", 
            "time_frame": "9 months"
        }, 
        "overall_official": {
            "affiliation": "Ev. Luth. Diakonissenanstalt Flensburg", 
            "last_name": "Stefan M\u00fcller-H\u00fclsbeck, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary patency of target lesion at 9-months assessed by duplex ultrasound as adjudicated by an independent core laboratory.", 
            "measure": "Primary patency", 
            "safety_issue": "Yes", 
            "time_frame": "9-months"
        }, 
        "reference": {
            "PMID": "21953370", 
            "citation": "Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011 Oct 1;4(5):495-504. doi: 10.1161/CIRCINTERVENTIONS.111.962324. Epub 2011 Sep 27."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820637"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boston Scientific Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston Scientific Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}